DE69721120D1 - Verwendung von menschlichen Chemokin beta-9 zur Behandlung von Atemnotsyndrom bei Erwachsenen - Google Patents
Verwendung von menschlichen Chemokin beta-9 zur Behandlung von Atemnotsyndrom bei ErwachsenenInfo
- Publication number
- DE69721120D1 DE69721120D1 DE69721120T DE69721120T DE69721120D1 DE 69721120 D1 DE69721120 D1 DE 69721120D1 DE 69721120 T DE69721120 T DE 69721120T DE 69721120 T DE69721120 T DE 69721120T DE 69721120 D1 DE69721120 D1 DE 69721120D1
- Authority
- DE
- Germany
- Prior art keywords
- adults
- treatment
- respiratory distress
- distress syndrome
- human chemokine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/195—Chemokines, e.g. RANTES
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
- A61K31/175—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine having the group, >N—C(O)—N=N— or, e.g. carbonohydrazides, carbazones, semicarbazides, semicarbazones; Thioanalogues thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
- A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
- A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
- Cephalosporin Compounds (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US1787196P | 1996-05-14 | 1996-05-14 |
Publications (2)
Publication Number | Publication Date |
---|---|
DE69721120D1 true DE69721120D1 (de) | 2003-05-28 |
DE69721120T2 DE69721120T2 (de) | 2003-12-04 |
Family
ID=21785003
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE69721120T Expired - Fee Related DE69721120T2 (de) | 1996-05-14 | 1997-05-12 | Verwendung von menschlichen Chemokin beta-9 zur Behandlung von Atemnotsyndrom bei Erwachsenen |
Country Status (5)
Country | Link |
---|---|
US (5) | US6290948B1 (de) |
EP (1) | EP0807439B1 (de) |
JP (2) | JPH1053533A (de) |
DE (1) | DE69721120T2 (de) |
DK (1) | DK0807439T3 (de) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6811773B1 (en) | 1993-12-22 | 2004-11-02 | Human Genome Sciences, Inc. | Human monocyte colony inhibitory factor (M-CIF) polypeptides |
US6451562B1 (en) | 1993-12-22 | 2002-09-17 | Human Genome Sciences, Inc. | Polypeptides encoding myeloid progenitor inhibitory factor-1 (MPIF-1) polynucleotides |
US6488925B2 (en) | 1993-12-22 | 2002-12-03 | Human Genome Sciences, Inc. | Macrophage inflammatory protein-4 (MIP-4) polypeptides |
US6495129B1 (en) | 1994-03-08 | 2002-12-17 | Human Genome Sciences, Inc. | Methods of inhibiting hematopoietic stem cells using human myeloid progenitor inhibitory factor-1 (MPIF-1) (Ckbeta-8/MIP-3) |
PL326080A1 (en) * | 1995-09-29 | 1998-08-17 | Smithkline Beecham Corp | Short forms of chemokin beta-8 |
US6713052B1 (en) | 1995-10-24 | 2004-03-30 | Human Genome Sciences, Inc. | Method of mobilizing stem cells with chemokine β-8 |
US6290948B1 (en) * | 1996-05-14 | 2001-09-18 | Smithkline Beecham Corporation | Method of treating sepsis and ARDS using chamohine beta-10 |
US6632425B1 (en) | 1997-03-20 | 2003-10-14 | Human Genome Sciences, Inc. | Chemokine compositions |
US7067117B1 (en) | 1997-09-11 | 2006-06-27 | Cambridge University Technical Services, Ltd. | Compounds and methods to inhibit or augment an inflammatory response |
US6989435B2 (en) | 1997-09-11 | 2006-01-24 | Cambridge University Technical Services Ltd. | Compounds and methods to inhibit or augment an inflammatory response |
KR19990042713A (ko) * | 1997-11-27 | 1999-06-15 | 허일섭 | 사람에서 분리한 c 6 베타-케모카인 lkn-1의 cdna 및 재조합 lkn-1의 제조방법 |
AU1824499A (en) * | 1997-12-30 | 1999-07-19 | Chiron Corporation | Human cxc chemokine ((tim-1)) |
US6495128B1 (en) | 1998-11-10 | 2002-12-17 | Human Genome Sciences, Inc. | Human chemokine β-7 deletion and substitution proteins |
US7238711B1 (en) | 1999-03-17 | 2007-07-03 | Cambridge University Technical Services Ltd. | Compounds and methods to inhibit or augment an inflammatory response |
AU2002221099A1 (en) * | 2000-12-08 | 2002-06-18 | Takeda Chemical Industries Ltd. | Combination drugs |
EP1641484A2 (de) * | 2003-05-09 | 2006-04-05 | Schering Aktiengesellschaft | Behandlung von entzündlichen atemwegserkrankungen |
US8329169B2 (en) | 2003-05-15 | 2012-12-11 | Genentech, Inc. | Methods and compositions for the prevention and treatment of sepsis |
JP2008523083A (ja) * | 2004-12-08 | 2008-07-03 | イムノメディクス, インコーポレイテッド | 炎症性疾患および免疫調節不全疾患、感染性疾患、病的血管新生およびがんの免疫療法および検出のための方法および組成物 |
ES2550389T3 (es) | 2007-03-28 | 2015-11-06 | Universidad De Barcelona | Producto de CD6 para el tratamiento de enfermedades infecciosas y procesos inflamatorios relacionados |
SG191716A1 (en) | 2010-11-19 | 2013-08-30 | Toshio Imai | Neutralizing anti-ccl20 antibodies |
EP3541407A1 (de) | 2016-11-18 | 2019-09-25 | Universitat de Barcelona | Kombinierte cd6- und imipenem-therapie zur behandlung von infektionskrankheiten und damit verbundenen entzündungsprozessen |
Family Cites Families (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4897348A (en) * | 1983-08-25 | 1990-01-30 | Sri International | Recombinant materials and methods for producing human connective tissue-activating peptide-III and analogs thereof |
US4897338A (en) * | 1987-08-03 | 1990-01-30 | Allied-Signal Inc. | Method for the manufacture of multilayer printed circuit boards |
AU634508B2 (en) * | 1988-12-08 | 1993-02-25 | Sandoz Ag | Neutrophil-activating peptide-2 |
US5212073A (en) * | 1989-05-12 | 1993-05-18 | Genetics Institute, Inc. | Process for producing human JE cytokine |
US5179078A (en) * | 1989-05-12 | 1993-01-12 | Dana Farber Cancer Institute | Method of suppressing tumor formation in vivo |
CA2064558C (en) * | 1989-09-25 | 2001-01-30 | Ian B. Pragnell | Method for inhibiting growth of stem cells |
NZ237202A (en) * | 1990-02-23 | 1994-01-26 | Bristol Myers Squibb Co | Composition containing beta-lactam antibiotic and cationic oligopeptide |
JPH06503710A (ja) * | 1990-09-14 | 1994-04-28 | カイロン コーポレイション | 酵母細胞におけるマクロファージ誘導タンパク質(mip)の発現 |
US5401651A (en) * | 1991-10-16 | 1995-03-28 | Walz; Alfred | DNA encoding ENA-78, a neutrophil activating factor |
US5306709A (en) * | 1991-11-15 | 1994-04-26 | The University Of Pennsylvania | Suppression of megakaryocytopoiesis by macrophage inflammatory proteins |
US5413778A (en) * | 1992-10-05 | 1995-05-09 | The Regents Of The University Of Michigan | Labelled monocyte chemoattractant protein material and medical uses thereof |
US5346686A (en) * | 1992-10-05 | 1994-09-13 | Mallinckrodt Medical, Inc. | Labelled interleukin-8 and medical uses thereof |
US5474983A (en) * | 1993-03-15 | 1995-12-12 | The Research Foundation Of State University Of New York | Method of inhibiting pro-inflammatory mediator release from basophils and mast cells |
US5346685A (en) * | 1993-04-23 | 1994-09-13 | Mobil Oil Corp. | Synthetic porous crystalline MCM-51, its synthesis and use |
JPH0789866A (ja) * | 1993-09-21 | 1995-04-04 | Nippon Kayaku Co Ltd | 感染防御剤 |
CA2179606A1 (en) * | 1993-12-22 | 1995-06-29 | Haodong Li | Macrophage inflammatory proteins-3, -4 and -1.gamma. |
EP0770086A4 (de) * | 1994-05-16 | 1998-07-15 | Human Genome Sciences Inc | Makrophagenmigration inhibierender faktor-3 |
PT799311E (pt) * | 1994-08-23 | 2005-05-31 | Human Genome Sciences Inc | Quimiocina beta-9 humana |
DE69433648T2 (de) * | 1994-08-23 | 2005-02-17 | Human Genome Sciences, Inc. | Menschliche chemokin-polypeptide |
WO1996009062A1 (en) * | 1994-09-23 | 1996-03-28 | University Of Nebraska Board Of Regents | Polypeptide agonists and antagonists of human interleukin-8 |
US5602008A (en) * | 1994-11-29 | 1997-02-11 | Incyte Pharmaceuticals, Inc. | DNA encoding a liver expressed chemokine |
CN1190991A (zh) * | 1995-06-05 | 1998-08-19 | 人类基因组科学公司 | 人类趋化因子β-11和人类趋化因子α-1 |
DE69533627T2 (de) * | 1995-06-06 | 2005-10-13 | Human Genome Sciences, Inc. | Humanes chemokin beta-13 |
WO1996039520A1 (en) * | 1995-06-06 | 1996-12-12 | Human Genome Sciences, Inc. | Human chemokine beta-12 |
EP0871664B1 (de) * | 1995-10-24 | 2004-01-02 | Smithkline Beecham Corporation | Mobilisierung von haematopoietischen stammzellen durch ein chemokin |
ZA968896B (en) * | 1995-10-24 | 1997-04-24 | Smithkline Beecham Corp | Method of mobilizing hematopoietic stem cells |
ZA969721B (en) * | 1995-11-21 | 1997-11-28 | Smithkline Beecham Corp | Method of treating sepsis. |
EP0885293B1 (de) * | 1996-02-23 | 2006-06-07 | Human Genome Sciences, Inc. | Menschliche chemokin-polypeptide. |
US6509313B1 (en) * | 1996-02-28 | 2003-01-21 | Cornell Research Foundation, Inc. | Stimulation of immune response with low doses of cytokines |
CA2249995A1 (en) | 1996-03-18 | 1997-09-25 | Human Genome Sciences, Inc. | Chemokine alpha 3 |
CA2250576A1 (en) * | 1996-03-27 | 1997-10-02 | Icos Corporation | Monocyte chemotactic protein-5 materials and methods |
US6290948B1 (en) * | 1996-05-14 | 2001-09-18 | Smithkline Beecham Corporation | Method of treating sepsis and ARDS using chamohine beta-10 |
GB9617923D0 (en) * | 1996-08-28 | 1996-10-09 | Smithkline Beecham Plc | Novel receptor |
WO1998011226A2 (en) * | 1996-09-10 | 1998-03-19 | Schering Corporation | Mammalian chemokines, related reagents |
WO1998014573A1 (en) * | 1996-09-30 | 1998-04-09 | The General Hospital Corporation | Mcp-4 and mcp-5: novel chemokines |
-
1997
- 1997-05-06 US US08/852,212 patent/US6290948B1/en not_active Expired - Fee Related
- 1997-05-12 DK DK97303204T patent/DK0807439T3/da active
- 1997-05-12 DE DE69721120T patent/DE69721120T2/de not_active Expired - Fee Related
- 1997-05-12 EP EP97303204A patent/EP0807439B1/de not_active Expired - Lifetime
- 1997-05-14 JP JP9161779A patent/JPH1053533A/ja active Pending
-
2000
- 2000-02-01 US US09/496,273 patent/US6406688B1/en not_active Expired - Fee Related
- 2000-10-25 JP JP2000325433A patent/JP2001122801A/ja not_active Withdrawn
-
2002
- 2002-03-25 US US10/103,859 patent/US20020155094A1/en not_active Abandoned
- 2002-03-26 US US10/105,285 patent/US20020141972A1/en not_active Abandoned
- 2002-03-28 US US10/107,371 patent/US20020146390A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US20020146390A1 (en) | 2002-10-10 |
US20020141972A1 (en) | 2002-10-03 |
US6406688B1 (en) | 2002-06-18 |
EP0807439B1 (de) | 2003-04-23 |
DK0807439T3 (da) | 2003-08-11 |
US6290948B1 (en) | 2001-09-18 |
DE69721120T2 (de) | 2003-12-04 |
JPH1053533A (ja) | 1998-02-24 |
US20020155094A1 (en) | 2002-10-24 |
JP2001122801A (ja) | 2001-05-08 |
EP0807439A3 (de) | 1998-03-11 |
EP0807439A2 (de) | 1997-11-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69721120D1 (de) | Verwendung von menschlichen Chemokin beta-9 zur Behandlung von Atemnotsyndrom bei Erwachsenen | |
DE69726245D1 (de) | Befeuchtungsgerät zur Behandlung von Atemstillstand im Schlaf | |
DE69941566D1 (de) | N-acetylhomotaurinate zur verwendung in der behandlung von hyperkinesie | |
ATE246500T1 (de) | Verwendung von anti-mikrotubuli mitteln zur behandlung von entzündlichen erkrankungen der atemwege | |
ATE349428T1 (de) | Prostaglandinagoniste und deren verwendung zur behandlung von knochenerkrankungen | |
DE69916686D1 (de) | Gerät zur Behandlung von Atemstillstand im Schlaf | |
DE69600307D1 (de) | Beatmungsgerät zur Behandlung von Ateminsuffizienzen | |
DE69830660D1 (de) | Behandlung von atemstillstand im schlaf | |
DE69631157D1 (de) | Pharmazeutische Zubereitung zur Verwendung in der Behandlung von Diabetes | |
DE69823459D1 (de) | Herzbehandlungssystem zur Feststellung und Behandlung von Herzversagen | |
DE69202207D1 (de) | Verfahren zur Herstellung von 1-Chlor-1,1,3,3,3-Pentafluorpropan und von 1,1,1,3,3,3-Hexafluorpropan. | |
DE69739303D1 (de) | Vorrichtung zur thermischen behandlung von gewebe | |
ATE214274T1 (de) | Antikonvulsiva zur verwendung bei der behandlung von amyotropischer lateralsklerose | |
TR199901772T2 (de) | ||
DE68910175D1 (de) | Adsorbermodul sowie Adsorberapparat zur Behandlung von Vollblut. | |
DE59206237D1 (de) | Strahlmittel, Verfahren zur Herstellung desselben sowie Verwendung des Strahlmittels | |
DE69824576D1 (de) | Verwendung von tetrahydropyridinderivaten zur herstellung von arzneimitteln zur behandlung demyelinisierender erkrankungen | |
DE69216615D1 (de) | Entwässerte Blutzellen und Verfahren zur Herstellung | |
DE69734296D1 (de) | Neue dikaffeoylchinasäurederivate und deren verwendung zur behandlung von hepatitis b | |
ATE347372T1 (de) | Vakzine zur behandlung von mycosen | |
DE69531132D1 (de) | Blattförmiger Sauerstoff-Absorber und Verfahren zur Herstellung | |
DE69633985D1 (de) | Behandlung von Chromoxid und dessen Verwendung in der katalytischen Herstellung von Vinylfluorid | |
DE69434777D1 (de) | Verwendung von Relaxin zur Herstellung von therapeutischen Mitteln | |
DE60027429D1 (de) | Dihydrobenzodiazepinen und deren verwendung zur behandlung von dyslipidämien | |
ATE77560T1 (de) | Verwendung von 2-oxo-pyrrolidin-1-acetamid zur bestimmung der glomerulaeren filtrationsrate beim menschen. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition | ||
8339 | Ceased/non-payment of the annual fee |